Pyc Therapeutics Ltd has released a press release.
Approval to Progress Kidney Disease Trial to Next Stage
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- Fourth Drug Program Progressing to Human Trials
- FDA Alignment on Registrational Trial Design RP11 Program
- SRC Approves Dose Escalation in ADOA Clinical Trial
- Approval to Escalate Dosing in Kidney Disease Trial
- Presentation of Clinical Proof of Concept in Lead Program
Later from PYC Therapeutics
- Approval to Escalate Dosing in Kidney Disease Clinical Trial
- Appendix 4E
- PKD Program - Presentation of Safety Data at ANZSN
- ADOA Program - Presentation of Clinical Data at NOSA 2025
- Change of Managing Director
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics